Incyte Presents Results From A Phase I Trial Of INCB024360, A Novel Oral Inhibitor Of Indoleamine Dioxygenase-1 (IDO1), At ASCO
Incyte Corporation (Nasdaq: INCY) presented preliminary results today
from the ongoing Phase I clinical trial for its oral indoleamine
dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of
Incyte Corporation (Nasdaq: INCY) presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. IDO1 expression in human tumors is associated with poor prognosis, and IDO1 inhibition may provide a new approach to increase survival in patients with a variety of solid tumors. “For cancer patients, elevated IDO levels correlate with poor outcomes. A compound, such as INCB024360, which can significantly inhibit IDO levels at doses that appear well-tolerated in a Phase I study, may offer a new therapeutic approach for these patients. We look forward to seeing this hypothesis tested in upcoming Phase II trials in patients with advanced ovarian cancer and advanced melanoma, a cancer where immunomodulatory therapies have promise,” stated presenting author Gregory Beatty, MD, PhD, an Assistant Professor in the Department of Medicine, Hematology/Oncology Division, at the Abramson Cancer Center of the University of Pennsylvania Perelman School of Medicine in Philadelphia. The findings of the Phase I study were reported during an oral presentation, Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. The Phase I study of INCB024360 is an open-label, single-agent dose-escalation trial in patients with advanced cancers. The preliminary findings confirmed significant IDO1 expression in various tumors, including bladder, colorectal and breast cancers. Using two independent assays, IDO1 inhibition was observed in all patients receiving the compound, and treatment with INCB024360 resulted in greater than 90 percent inhibition of IDO1 activity when administered at doses above 300 mg twice a day. The compound is generally well-tolerated at these doses with the most common adverse events being grade 1 and 2 fatigue. A maximum tolerated dose has not been identified. The slides used during the presentation can be accessed at: 2012 ASCO - INCB024360 presentation. About Indoleamine Dioxygenase-1 (IDO1) IDO1 is an enzyme that is expressed in tumor cells and in activated immune cells. IDO1 expression dampens the immune response by degrading the amino acid tryptophan and rendering tumor-specific cytotoxic T lymphocytes functionally inactive or unable to attack a person’s cancer cells. In preclinical models, blocking IDO1 activity can directly influence the ability of tumor-bearing animals to reject tumors, and IDO1 inhibition increases the efficacy of chemotherapeutic agents without increased toxicity. These effects are not observed in immune deficient animals, suggesting that the results depend on the presence of an active immune system. IDO1 is overexpressed by a variety of human tumor types and is chronically activated in some patients with cancer.